Akcea names Damien Devitt as CEO

Damien Devitt, who has been interim CEO of Akcea Therapeutics (NASDAQ:AKCA) since September 2019, has been promoted to CEO, effective immediately, and will continue to serve as a member of Akcea’s board.

“With his experience at both Ionis and Akcea, [Mr. Devitt] has the perspective and insight to lead Akcea at a time when the company is positioned to make rapid progress in advancing its global development and commercialization strategies,” Lynne Parshall, Akcea’s chairman, said in a statement.

Prior to joining Akcea, Mr. Devitt was chief business officer at Ionis Pharmaceuticals (NASDAQ:IONS) and previously served as SVP at Acadia Pharmaceuticals (NASDAQ:ACAD).

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.